Document is current

Article History

Received: 10 September 2020

Accepted: 3 December 2020

First Online: 4 January 2021

Ethics approval and consent to participate

: The clinical studies discussed in this review were conducted in accordance with ethical principles of the Declaration of Helsinki and Good Clinical Practice guidelines and were approved by each participating centre’s institutional review board or ethics committee. All patients provided written informed consent.

: Not applicable.

: PE has received research grants and consulting fees from Abbott, AbbVie, Bristol-Myers Squibb, Pfizer, UCB, Merck Sharp & Dohme, Roche, Novartis, Samsung, Takeda, Eli Lilly, Sanofi and Regeneron Pharmaceuticals, Inc. PD has received speaker fees from BMS, Galapagos and Eli Lilly and Company. AH has received grant/research support and speaker fees from Eli Lilly and Company. YT reports personal fees from Eli Lilly during the conduct of the study; grant support from Merck Sharp & Dohme and Eisai; grant support and personal fees from Mitsubishi-Tanabe, Takeda, Daiichi-Sankyo, Chugai, Bristol-Myers Squibb, Astellas and AbbVie; and personal fees from Pfizer, Teijin, Asahi-kasei, YL Biologics, Sanofi, Janssen and GlaxoSmithKline outside the submitted work. IdlT, EL and TH are employees and shareholders of Eli Lilly and Company.